Atara Biotherapeutics Company Insiders

ATRA Stock  USD 12.18  0.08  0.65%   
Atara Biotherapeutics employs about 165 people. The company is managed by 15 executives with a total tenure of roughly 7 years, averaging almost 0.0 years of service per executive, having 11.0 employees per reported executive. Analysis of Atara Biotherapeutics' management performance can provide insight into the company performance.
Joseph Newell  President
Executive Vice President Chief Technical Operations Officer
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Atara Biotherapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
For information on how to trade Atara Stock refer to our How to Trade Atara Stock guide.

Atara Biotherapeutics Management Team Effectiveness

The company has return on total asset (ROA) of (0.5748) % which means that it has lost $0.5748 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (20.1486) %, meaning that it created substantial loss on money invested by shareholders. Atara Biotherapeutics' management efficiency ratios could be used to measure how well Atara Biotherapeutics manages its routine affairs as well as how well it operates its assets and liabilities.

Atara Biotherapeutics Workforce Comparison

Atara Biotherapeutics is rated below average in number of employees category among its peers. The total workforce of Health Care industry is presently estimated at about 3,652. Atara Biotherapeutics holds roughly 165 in number of employees claiming about 5% of equities under Health Care industry.
The company has Profit Margin (PM) of (2.9) %, which may suggest that it does not properly executes on its current pricing strategies or is unable to control all of the operational costs. This is way below average. Similarly, it shows Operating Margin (OM) of (0.62) %, which suggests for every $100 dollars of sales, it generated a net operating loss of $0.62.

Atara Biotherapeutics Insider Trading

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Atara Biotherapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Atara Biotherapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Atara Biotherapeutics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

Atara Biotherapeutics Notable Stakeholders

An Atara Biotherapeutics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Atara Biotherapeutics often face trade-offs trying to please all of them. Atara Biotherapeutics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Atara Biotherapeutics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Pascal DVMCEO PresidentProfile
Joseph NewellExecutive Vice President Chief Technical Operations OfficerProfile
Rajani MDSenior OfficerProfile
Eric HyllengrenExecutive OfficerProfile
Jakob MDEx RDProfile
Kerry DalyHead CommunicationsProfile
Jill HenrichExecutive QualityProfile
Utpal MBAEx CFOProfile
Alex ChapmanVice RelationsProfile
Anhco NguyenExecutive OfficerProfile
Manher MDExecutive OfficerProfile
Amie KrauseChief OfficerProfile
Charlene BanardChief OfficerProfile
Amar MuruganExecutive OfficerProfile
Dan MaziaszExecutive OfficerProfile

About Atara Biotherapeutics Management Performance

The success or failure of an entity such as Atara Biotherapeutics often depends on how effective the management is. Atara Biotherapeutics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Atara management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Atara management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. The company was incorporated in 2012 and is headquartered in South San Francisco, California. Atara Biotherap operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 578 people.
Please note, the presentation of Atara Biotherapeutics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Atara Biotherapeutics' management is honest, while the outside auditors are strict and uncompromising. Please utilize our Beneish M Score to check the likelihood of Atara Biotherapeutics' management manipulating its earnings.

Atara Biotherapeutics Workforce Analysis

Traditionally, organizations such as Atara Biotherapeutics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Atara Biotherapeutics within its industry.

Atara Biotherapeutics Manpower Efficiency

Return on Atara Biotherapeutics Manpower

Revenue Per Employee52K
Revenue Per Executive571.5K
Net Loss Per Employee1.7M
Net Loss Per Executive18.4M

Complementary Tools for Atara Stock analysis

When running Atara Biotherapeutics' price analysis, check to measure Atara Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Atara Biotherapeutics is operating at the current time. Most of Atara Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Atara Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Atara Biotherapeutics' price. Additionally, you may evaluate how the addition of Atara Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Price Transformation
Use Price Transformation models to analyze the depth of different equity instruments across global markets
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Alpha Finder
Use alpha and beta coefficients to find investment opportunities after accounting for the risk